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In-vitro evaluation of TiO2 nanotubes as cefuroxime carriers on 1 
orthopedic implants for the prevention of periprosthetic joint 2 
infections 3 
 4 
Structured Abstract: 5 
Context: The prevention of periprosthetic joint infections requires an antibiotic 6 
prophylactic therapy, which could be delivered locally using titanium dioxide 7 
nanotubes as novel reservoirs created directly on the orthopaedic implant titanium 8 
surface. 9 
Objective: In this study, the influence of several parameters that could impact the use 10 
of titanium dioxide nanotubes as cefuroxime carriers was investigated. 11 
Method: Cefuroxime loading and release was studied for 90 minutes with three nano-12 
topography conditions (nano-smooth, nano-rugged and nano-tubular), two 13 
cefuroxime loading solution concentrations (150 mg/mL and 25 mg/mL) and two 14 
nano-tubular crystalline structures. 15 
Results: In all tested conditions, maximum amount of cefuroxime was obtained within 16 
two minutes. For both cefuroxime loading solution concentrations, nano-smooth 17 
samples released the least cefuroxime, and the nano-tubular samples released the 18 
most, and a six-fold increase in the concentration of the cefuroxime loading increased 19 
the amount of cefuroxime quantified by more than seven times, for all tested nano-20 
topographies. However, the nano-tubes’ crystalline structure did not have any 21 
influence on the amount of cefuroxime quantified.  22 
Conclusion: The results demonstrated that the surface nano-topography and loading 23 
solution concentration influence the efficiency of titanium dioxide nanotubes as 24 
cefuroxime carriers and need to be optimized for use as novel reservoirs for local 25 
delivery of cefuroxime to prevent periprosthetic infections. 26 
 27 
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Introduction 57 
Total knee and hip arthroplasties (TKA and THA) are frequent orthopaedic 58 
procedures, with over 4,400,000 TKA and 2,100,000 THA having been performed 59 
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between 1998 and 2008 in the United States (Memtsoudis et al., 2012). 60 
Periprosthetic joint infection incidences vary notably with patient comorbidities, but 61 
are estimated to range between 0.86% to 1.1% for TKA and between 0.3% to 1.63% 62 
for THA (Dale et al., 2011; Jämsen et al., 2010; Ong et al., 2009; Phillips, 2006; 63 
Pulido et al., 2008). With the number of TKA and THA predicted to grow by nearly 64 
600% and more than 100% respectively between 2005 and 2030 in the United States 65 
(S. Kurtz et al., 2007; Iorio et al., 2008), the absolute number of periprosthetic joint 66 
infections is set to increase. The most prevalent etiological agents of orthopaedic 67 
infections are gram positive opportunistic cocci, namely Staphylococcus aureus and 68 
Staphylococcus epidermidis, responsible for more than two thirds of all infections 69 
(Campoccia et al., 2006; Montanaro et al., 2011). If surgical debridement combined 70 
with antibiotic therapy and implant retention is still possible in the early stages of 71 
infections, in the other cases a surgical revision with implant ablation and several 72 
weeks of intravenous antibiotic therapy is necessary to treat the infection completely 73 
(Cuckler, 2005; Senthi et al., 2011).  74 
A prophylactic systemic antibiotic treatment is recommended when using 75 
implantable medical devices such as articular implants (AlBuhairan et al., 2008; 76 
Meehan et al., 2009; Kuong et al., 2009; Gillespie and Walenkamp, 1996; Société de 77 
Pathologie Infectieuse de Langue Française (SPILF), 2009). Regrettably, due to the 78 
disturbed bone structure and local vascularity, caused by the trauma of the surgery, 79 
as well as probable initial bad distribution of antibiotics into the bone (Smilack et al., 80 
1976), it is thought that the achieved in situ concentrations might not be enough to 81 
exceed minimal inhibition concentrations (Schmidmaier et al., 2006; Zilberman and 82 
Elsner, 2008), leading to a suboptimal efficiency. 83 
Recently, the use of self-assembled titanium dioxide nanotubes (TiO2 NT) as 84 
reservoirs for localized antibiotic prophylactic therapy has been described (Ayon et 85 
al., 2006; Gulati et al., 2011; Kang et al., 2007; Losic and Simovic, 2009; Macak et 86 
al., 2007; Popat et al., 2007). Created directly on the titanium surface, TiO2 NT, in 87 
certain conditions, have been shown to improve osteoblast adhesion, reduce 88 
bacterial colonization and serve as a reservoir for drugs (Losic and Simovic, 2009; 89 
Gulati et al., 2011; Ghicov and Schmuki, 2009; Roy et al., 2011), possibly allowing an 90 
in situ release of antibiotics after the prosthesis implantation. 91 
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In this work, Cefuroxime, a second generation cephalosporin, was chosen as 92 
a model drug as its use is recommended by the American Academy of Orthopaedic 93 
surgeons (Meehan et al., 2009) and by the French Society of Anaesthesia and 94 
Intensive care (Société française d’anesthésie et de réanimation, 2011) for antibiotic 95 
prophylactic treatment in orthopaedic surgery. Moreover, to our knowledge, there is 96 
no data in the literature concerning the use of nanotubes as cefuroxime carriers. 97 
We studied the influence of several parameters that could have an impact on 98 
the use of TiO2 NT as a cefuroxime carrier: the surface nano-topography (smooth 99 
versus nano-rugged versus nanostructured titanium samples), the loading solution 100 
concentration (by comparing the use of a saturated solution of cefuroxime (150 101 
mg/mL) to a much lesser concentrated solution (25 mg/mL), for each nano-102 
topography condition) and the nanotube’s crystalline structure (annealed nanotubes 103 
versus non-annealed nanotubes).  104 
 105 
I. Materials and methods 106 
A. Sample preparation 107 
1. Titanium samples 108 
Unpolished titanium foil (99.6% purity, 0.1 mm thickness, Goodfellow, Lille France) 109 
was first cut into rectangular samples (2.5 X 1.5 cm), which were then degreased by 110 
successive 5 minutes sonications in trichloroethylene (VWR BDH Prolabo, Fontenay-111 
sous-Bois, France), acetone (Merck Millipore, Darmstadt, Germany) and methanol 112 
(UCB Pharma France, Colombes, France), then rinsed with deionised water, dried in 113 
the oven at 100 °C and finally cooled in a desiccator. The obtained samples are later 114 
on referred to as nano-smooth samples. 115 
To obtain nano-rugged surfaces, but without fully formed nanotubes, the as 116 
previously described cleaned titanium foil samples (smooth samples) were anodized 117 
by immersion to a height of 1.5 cm in a 0.4 wt. % HF aqueous solution with a 118 
platinium cathode, as schematized in Figure 1. The anodizing voltage was 119 
maintained at 20 V, for 80 seconds, at a constant temperature of 20 °C.  120 
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To obtain TiO2 nanotubes (nano-tubular samples), the anodization was carried out in 121 
the same conditions as described above but for 20 minutes. 122 
All experiments were conducted on the obtained nano-smooth, nano-rugged or nano-123 
tubular titanium foil. 124 
To convert the amorphous nanotubes into the mixed crystalline phases of anatase 125 
and rutile, some samples were annealed at 500°C for 2 hours under oxygen, with a 126 
heating and cooling rate of 5 °C min-1. 127 
 128 
2. Cefuroxime loading solutions 129 
A 150 mg/mL cefuroxime solution was prepared by dissolving 1.5 g of cefuroxime 130 
(Panpharma, Fougeres, France, batch No 104179) with sterile deionised water 131 
(VERSYLENE®, Fresenius Kabi, Louviers, France) to a total volume of 10 mL. 132 
 133 
3. Loading method and storage 134 
To load the samples with cefuroxime, an adapted soaking technique was used (Ayon 135 
et al., 2006; Kim et al., 2008). Each sample was immersed to a height of 1.5 cm, in 136 
either a 150 mg/ml or a 25 mg/mL solution of cefuroxime, for 30 minutes, in ambient 137 
daylight, at room temperature (22-26°C). At the end of the loading time, the samples 138 
were removed from the immersion solution and were immediately air blown to 139 
remove excess solution on the surface and to dry them. 140 
The samples were stored prior to loading and after loading, until cefuroxime 141 
quantification, in a climate chamber (BINDER GmbH, Tuttlingen, Germany), in the 142 
dark, at 25°C. 143 
 144 
B. Sample characterizations 145 
1. Structural characterizations 146 
The crystalline structure and phase of the TiO2 nanotube layers of a smooth, a non-147 
annealed and an annealed nano-tubular sample were determined by X-ray diffraction 148 
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(XRD) using a Scintag XRD X’TRA diffractometer with CuKα (λ = 1.54° radiation). 149 
The CuKβ radiation was filtered through a nickel filter. The diffraction pattern was 150 
achieved between 20 and 80◦ with a step angle of 0.05° and a scanning speed of 151 
0.01° per second.  152 
For the study of the surface nano-topography, structural characterization of a smooth, 153 
a nano-rugged and a nano-tubular sample was performed before and after drug 154 
loading with two different concentration cefuroxime solutions using a field emission 155 
scanning electron microscope (SEM). It was performed using a Supra 55 VP SEM 156 
(Carl Zeiss SMT, Nanterre, France) with secondary emission and in lens detector. 157 
The accelerating voltage and the working distance were respectively 3 kV and either 158 
5 or 6 mm (image dependent).  159 
Images were acquired at different scan sizes from the top surface. 160 
For the four different tested conditions of titanium foil nano-topography and crystalline 161 
structure (smooth, nano-rugged, non-annealed nano-tubular and annealed nano-162 
tubular), surface wettability was investigated using a drop shape analysis system 163 
(EasyDrop, Kruss, Hamburg, Germany). The contact angle was measured with a 164 
deionized water sensile droplet of 3 μL in ambient conditions. The measurement was 165 
taken 5 seconds after the deposition of the water droplet on the substrate. After 166 
measurement, the samples were cleaned, dried in nitrogen and stored in a 167 
desiccator. 168 
 169 
2. Cefuroxime quantification 170 
Each sample was placed into a known volume of sterile deionised water (5 or 10 mL 171 
depending on the estimated loaded quantity of cefuroxime), for 90 minutes. At 172 
determined times (1; 2; 5; 10; 15; 30; 60 and 90 minutes) a determined volume (1000 173 
µL) of release solution was collected and was replaced with the same volume of 174 
fresh sterile deionised water. 175 
The cefuroxime present in the collected sample was then quantified by HPLC 176 
composed of a PU-2080 Plus pump, and an AS-2055 Plus auto-sampler coupled with 177 
an UV/VIS spectrophotometer (UV-2075 Plus detector), from Jasco France 178 
(Bouguenais, France) 179 
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The HPLC separation column used was a 5 µm Lichrospher 100 RP 18 endcapped 180 
column (125 × 4.6 mm ID) (Macherey-Nagel EURL, Hoerd, France) 181 
The HPLC mobile phase was composed of 85/15 phosphate buffer/acetonitrile (v/v) 182 
mixture. The phosphate buffer used was a 0.1 mol/L solution of H2KPO4 (VWR 183 
International Pessac, France). The flow rate through the column for the analysis was 184 
set at 1 mL/min, with the column thermo regulated to a temperature of 35°C. The 185 
injection volume was of 20 µL. The detection wavelength was set up at 273 nm. 186 
Cefuroxime presents a retention time of 3.8 minutes. This chromatographic method is 187 
linear for concentrations ranging from 0.25 µg/mL to 20 µg/mL. The mean linear 188 
regression equation obtained is y = 35022x + 3014.7 (r2 = 0.9998), where x is the 189 
cefuroxime concentration and y the surface area of the corresponding peak. This 190 
method has acceptable accuracy and precision as the intra-assay and inter-assay 191 
coefficients of variation are below 5%. The limit of quantification of this method is of 192 
0.25 mg/mL. 193 
Cefuroxime release results were expressed in µg of cefuroxime over the loaded 194 
surface of anodized TiO2 (µg/cm
2).  195 
 196 
C. Tested parameters 197 
In this work, several parameters that could have an influence on the use of 198 
TiO2 NT as cefuroxime reservoirs were investigated.  199 
1. Influence of the surface nano-topography and loading 200 
solution concentration 201 
10 anodized (nano-tubular) non annealed Ti samples, 10 nano-rugged Ti samples, 202 
and 10 smooth Ti samples were prepared. 5 samples of each surface nano-203 
topography (15 samples in total) were loaded by immersion into a 150 mg/mL 204 
cefuroxime solution, as previously described, whilst the other 5 of each surface nano-205 
topography were loaded with a 25 mg/mL cefuroxime solution. 206 
2. Influence of the nanotube’s crystalline structure 207 
To see if annealing (heat treating) the nanotubes could impact their use as 208 
cefuroxime carriers as it modifies the nanotubes crystalline structure, annealed 209 
nanotubes were compared to non-annealed nanotubes. 210 
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7 non-annealed anodized samples and 7 annealed anodized samples were loaded 211 
by immersion in a 150 mg/mL cefuroxime solution, as previously described. 212 
 213 
D. Statistical considerations 214 
Statistical analysis was performed using a non-parametric Man-Whitney test. The 215 
difference was considered significant for a p-value ≤ 0.05. 216 
 217 
II. Results 218 
A. Structural characterization and surface wettability 219 
Figure 1 shows the current density time curve for Ti anodization obtained in our 220 
operating conditions, and illustrates the nanotube growth. SEM pictures of obtained 221 
nano-rugged and nano-tubular samples before loading are presented in Figure 2. 222 
Anodization occurred on both sides of the anodized samples. 223 
 224 
Nano-smooth non anodized samples typically are not microscopically smooth, but do 225 
not present any nano-scale ruggedness. Nano-rugged samples present nano-scale 226 
modifications with the formation of what seems to be shallow nanopores, whilst 227 
retaining their micro-scale topography. For the 20 minutes anodized samples, the 228 
formed nanotubes have dimensions of between 300 to 400 nm high and 70 to 90 nm 229 
in diameter. 230 
The XRD results are depicted in Figure 3. The peaks characteristic of anatase and 231 
rutile crystalline structure only appear after annealing at 500°C, and are not present 232 
in Ti foil or as-anodized Ti . 233 
 234 
Concerning the contact angle measurements (data summarised in Table I), 235 
anodization times of 80 seconds and 1200 seconds greatly increase the contact 236 
angle compared to smooth un-anodized titanium; however the contact angle 237 
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measured for an annealed nanotubular surface was lower than un-annealed 238 
anodised surface (Figure 4), and even lower than for a nano-smooth surface. 239 
 240 
 241 
B. Cefuroxime quantification 242 
SEM pictures of loaded samples are shown in Figure 5, with light grey/white 243 
colouring showing the titanium sample, and dark grey patches being cefuroxime 244 
deposits. In Figure 5(A), a relatively large deposit of cefuroxime can clearly be seen, 245 
with Figure 5(B) being a closer view of the phenomenon. Figure 5(C) and Figure 5(D) 246 
show how cefuroxime infiltrates and sometimes covers the nano-rugged surface 247 
nanopores, and in Figure 5(E) and Figure 5(F) the same can be said of the nano-248 
tubular surface. 249 
 250 
 251 
Figure 6 (A) and (B) shows the total amount of cefuroxime released over a 90 252 
minutes period from the different tested nano-surfaces with a 25 mg/mL and 150 253 
mg/mL cefuroxime loading solution, and Figure 7 shows the total amount of 254 
cefuroxime released over a 90 minutes period for annealed and un-annealed nano-255 
tubular surfaces. Table II summarise the statistical data of the different tested 256 
conditions at 90 minutes. 257 
Maximum cefuroxime release for the studied conditions was obtained within the first 258 
one or two minutes, and no additional cefuroxime release was detected for the rest of 259 
the release study period. 260 
For the nanotube length tested, there is no statistical influence of the nanotube’s 261 
crystalline structure on the amount of cefuroxime quantified (p = 0.28). Cefuroxime 262 
loading solution concentration does have a significant impact on cefuroxime 263 
quantities released (p = 0.001) as does the surface nano-topography, but only 264 
between the smooth samples and the nanotube samples for both tested loading 265 
solution concentrations (p = 0.04). The difference between the nano-rugged surface 266 
samples and the nanotubular surface samples is not statistically significant, for 267 
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neither loading solution concentrations (p = 0.08). The difference in cefuroxime 268 
release is significant between the smooth and nano-rugged surface samples only for 269 
a loading solution concentration of 25 mg/mL (p = 0.02). 270 
 271 
 272 
 273 
III. Discussion 274 
The aim of this work was to study several conditions which where hypothesised to 275 
influence the use of TiO2 nanostructures as cefuroxime carriers. 276 
Firstly, to try and characterize whether nanotubes can be used as cefuroxime 277 
reservoirs, 3 different nano-topography conditions were compared: smooth, nano-278 
rugged, nano-tubular. After loading, the smooth samples released the least 279 
cefuroxime (median 49.89 µg/cm2), and the nano-tubular samples released the most 280 
(median 70.03 µg/cm2). The difference between the smooth samples and 281 
nanotubular samples was statistically different, for both loading solution 282 
concentrations, but was much more pronounced for the 25 mg/mL loading solution 283 
(4.4-fold increase) when compared to the 150 mg/mL loading solution (40% 284 
increase). This could indicate either a loading of the nanotubes (penetration of 285 
cefuroxime into the tubes), or an increased surface adsorption, mediated by the 286 
nanotubes, or both. It could also be possible the cefuroxime penetrated the 287 
interstices visible between the nanotubes. Despite the differences not being 288 
significant between the nano-rugged samples and the smooth and nanotubular 289 
samples, the quantities of cefuroxime released by the nano-rugged samples are 290 
intermediate between the smooth and the nanotubular samples (67.89 µg/cm2). 291 
There is a statistical difference in released cefuroxime from samples loaded with a 292 
150 mg/mL cefuroxime solution when compared to samples loaded with a 25 mg/mL 293 
solution, for all tested surface nano-topographies, which indicates an influence of the 294 
loading solution concentration, which is what was expected. However, despite there 295 
being a fixed six-fold  difference in concentration between the 25 mg/mL and the 150 296 
mg/mL, the obtained difference in quantified cefuroxime was greater, and varied 297 
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depending on the nano-topography (24-fold, 20-fold and 7.7-fold for respectively the 298 
nano-smooth, nano-rugged and nano-tubular topographies). Such a difference is 299 
difficult to explain by just the results’ variability. One explanation is that despite a 300 
thorough air blowing cleaning procedure, surface adsorption of cefuroxime accounts 301 
for an important percentage of total loaded and released drug.  302 
TiO2 exists naturally in 3 crystalline phases, anatase, rutile and brookite (Roy et al., 303 
2011), yet after their electrochemical formation, TiO2 nanotubes are amorphous. By 304 
annealing (heat treating), the nanotubes can be converted to anatase or rutile, which 305 
changes notably the TiO2 nanotubes electrochemical and photocatalytical properties, 306 
but without notably altering the nanotube’s morphological characteristics (Lin et al., 307 
2011; Yu and Wang, 2010). In this work, annealed nanotubes did release more 308 
cefuroxime than non-annealed, but the difference was not statistically significant, 309 
notably due to the observed large variations of cefuroxime release within the 310 
annealed group. The annealed nano-tubular surfaces were however much more 311 
hydrophilic than the un-annealed nano-tubular surfaces, with a contact angle of 42° 312 
versus 120°for the un-anodized nano-tubular. In the conditions of this assay, it is 313 
therefore hard to draw any conclusions on the real influence of the crystalline state.  314 
The relatively high cefuroxime quantities quantified with the nano-smooth samples 315 
could be linked to moderate surface wettability, as expressed by the measure of 316 
water droplet contact angles, as the contact angle for such a surface was measured 317 
to be 77°. By contrast, non-annealed anodized surfaces (nano-rugged and nano-318 
tubular) had contact angles measured to be around 120°, expressing a more 319 
hydrophobic state, and yet released after loading more cefuroxime. Such results 320 
could be in favour of nanotube loading and release of cefuroxime, independently of 321 
the surfaces’ wettability, at least for the tested conditions.  322 
However, due to the small number of samples, the statistical power of the used test is 323 
probably insufficient to identify small differences between certain tested conditions. 324 
 325 
In our work, the drug release was nearly immediate, and is much faster than reported 326 
in other studies. Popat et al report loaded bovine serum albumin (BSA) and lysozyme 327 
using a pipetting method onto unpolished titanium samples with similar TiO2 328 
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nanotubes and obtained maximum release times that varied between 25 and 110 329 
minutes (Popat et al., 2007). Using a similar method, Aninwene et al loaded 330 
penicillin/streptomycin or dexamethasone and obtained drug elution for 3 days 331 
(Aninwene et al., 2008). The very fast release obtained here could be explained by 332 
high Cefuroxime water solubility (150 mg/mL), or by a surface layer of Cefuroxime, or 333 
possibly by both. Despite our cleaning method, SEM images showed significant 334 
Cefuroxime deposit on the surface of the TiO2 layer, on samples with different nano-335 
topography, possibly linked to the surface micro-topography. However, since nano-336 
tubular samples released significantly more Cefuroxime than smooth samples, it 337 
seems quite plausible that Cefuroxime penetrated at least partially into the 338 
nanotubes.  339 
Longer release times have been reported. Peng et al, also using unpolished TiO2 340 
nanotube surfaces and a consistent cleaning technique, found that elution kinetics of 341 
paclitaxel and BSA were influences by nanotube height and pore diameter (Peng et 342 
al., 2009), with nanotubes of 5 µm height and 100 nm of diameter releasing the most 343 
drug for up to 3 weeks.  344 
Therefore, in this study, the thickness of the nanotube layer could impact the 345 
maximum loading capacity of the tubes, as the longer the tube, the more volume it 346 
could contain. It could be possible that 400 nm of length is not enough to allow a 347 
significant amount of drug into the nanotubes, with regard to the potential surface 348 
adsorption. Therefore, any conclusions about the impact of the nanotubes’ crystalline 349 
structure might be premature, as the 400 nm high nanotubes could have been loaded 350 
at maximum capacity regardless of the surface wettability.  351 
In this work, the titanium foil used for the experiments was unpolished, and wasn’t 352 
microscopically smooth. This could have an impact on cefuroxime adsorption, as 353 
SEM structural characterization of samples with different nano-topographies, loaded 354 
with cefuroxime, showed an inhomogeneous cefuroxime spread. The microscopic 355 
surface features could lead to the formation of “beds” of cefuroxime, protected from 356 
the surface cleaning procedure. It has also already been hypothesized that in 357 
previous studies at least a significant amount of drug stayed on the surface and did 358 
penetrate into the nanotubes (Peng et al., 2009). These microscopic features could 359 
also account for the high variability between samples of the same series. Also, 360 
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surface adsorption could account for the instant burst-like release that was observed. 361 
Therefore, it would seem that in order to more accurately measure the exact quantity 362 
of drug actually loaded and then released by the nanotubes, microscopically smooth 363 
samples are needed, as well as an adequate and validated surface cleaning method. 364 
 365 
Several improvements could be made to this study. To achieve a microscopically 366 
smooth surface, a polishing method (electro-chemical polishing or physical polishing) 367 
could have been used. The effects of micro-scale ruggedness would therefore be 368 
reduced. Also, higher nanotubes could offer improved loading volume and drug 369 
storage capacity, and could also improve loading and elution kinetics. 370 
 371 
The work presented here seems to indicate that some parameters, like nanotube 372 
height and the loading solution concentration, have more influence on cefuroxime 373 
release from TiO2 nanotubes, whereas the crystalline structure of the nanotubes 374 
didn’t influence the amount of cefuroxime released. The nano-tubular samples 375 
released more cefuroxime than nano-smooth or nano-rugged samples, for both 150 376 
mg/mL and 25 mg/mL cefuroxime loading concentrations. However, cefuroxime 377 
release kinetics were too fast for lasting local drug delivery, and need to be extended. 378 
Longer nanotubes could increase the amount of cefuroxime loaded and release 379 
times, but might also increase overall fragility, and thus need to be tested. Also, the 380 
antibacterial efficacy of such a delivery method using cefuroxime still needs to be 381 
investigated. 382 
 383 
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 480 
 481 
 482 
Figure 1: Current density time curve with experimental setup. Nanotubes appear to 483 
be fully formed as of 20 minutes (1200 seconds) of anodizing time (d). The nano-484 
rugged surface was obtained with an anodizing time of 80 seconds, which 485 
corresponds to the low point of current density curve, between stage (a) and (b). 486 
 487 
 488 
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489 
 490 
Figure 2 (A), (B), (C) and (D): Surface topography of a nano-rugged (A) and (B) and 491 
nano-tubular (C) and (D) anodized TiO2 sample by SEM, before loading. 492 
 493 
 494 
Figure 3: X-ray diffractogram of smooth Ti foil (bottom graph), anodized (Anodic 495 
TiO2, middle graph) and 500°C annealed anodized titanium foil (top graph) with two 496 
peaks (A and R) corresponding to respectively the anatase and rutile crystalline 497 
phase. 498 
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 499 
Figure 4: (A) un-annealed nano-tubular sample and (B) annealed nano-tubular 500 
sample 501 
  502 
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504 
505 
 506 
Figure 5: (A) and (B): smooth titanium sample after cefuroxime loading, with (B) 507 
being a close up view of (A). (C) and (D): nano-rugged titanium sample with 508 
cefuroxime deposit and infiltration in the surface nanopores, with (D) being a close up 509 
view of (C). (E) and (F): nano-tubular titanium sample with cefuroxime deposit and 510 
infiltration in the surface nanopores. 511 
 512 
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 514 
Figure 6: Total amount of released cefuroxime during 90 minutes for the different 515 
tested nano-topography and cefuroxime loading solution conditions 516 
 517 
 518 
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 519 
Figure 7: Total amount of cefuroxime released during 90 minutes for amorphous and 520 
crystalline structures 521 
 522 
 523 
Table I : Contact angle measurement data 524 
 525 
 526 
Table II : Statistical data for the different tested conditions at 90 minutes 527 
528 
  529 
Measured contact angle Confidence intervalle 95%
1,90
0,67
Mean contact angle
77,18
122,00
118,00
41,73Annealed nano-tubular surface
Non-annealed nano-rugged surface 1,95
0,72
Nano-smooth surface
Non-annealed nano-tubular surface
Number of 
samples
Median total quantity of 
Cefuroxime (µg/cm2)
Interquartile 
range
Mean total quantity of 
Cefuroxime (µg/cm2)
Standard 
deviation
Variation 
coefficient (%)
25 mg/mL nano-smooth 3 2,07 0,55 2,13 0,28 13,2
25 mg/mL nano-rugged 4 3,45 1,22 3,46 0,95 27,4
25 mg/mL nano-tubular 4 9,09 1,58 8,77 0,84 9,6
150 mg/mL nano-smooth 4 49,89 15,61 50,00 10,06 20,1
150 mg/mL nano-rugged 4 67,89 17,84 63,86 9,07 14,2
150 mg/mL nano-tubular 4 70,03 10,38 71,17 9,75 13,7
Non annealed 7 76,99 21,76 78,11 15,40 19,7
Annealed 7 87,28 72,21 105,90 43,44 41,0
Surface nano-
topography
and
Loading solution 
concentration
Crystalline structure
Cefuroxime release at t = 90 minutes
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